# DRAFT landscape of COVID- 19 candidate vaccines – 30 April 2020

**DISCLAIMER:**

**These landscape documents have been prepared by the World Health Organization (WHO) for information purposes only concerning the 2019-2020 global of the novel
coronavirus. Inclusion of any particular product or entity in any of these landscape documents does not constitute, and shall not be deemed or construed as, any
approval or endorsement by WHO of such product or entity (or any of its businesses or activities). While WHO takes reasonable steps to verify the accuracy of the
information presented in these landscape documents, WHO does not make any (and hereby disclaims all) representations and warranties regarding the accuracy,
completeness, fitness for a particular purpose (including any of the aforementioned purposes), quality, safety, efficacy, merchantability and/or non-infringement of any
information provided in these landscape documents and/or of any of the products referenced therein. WHO also disclaims any and all liability or responsibility
whatsoever for any death, disability, injury, suffering, loss, damage or other prejudice of any kind that may arise from or in connection with the procurement,**

# DRAFT landscape of COVID- 19 candidate vaccines –

# 30 April 2020

8 candidate vaccines in clinical evaluation

94 candidate vaccines in preclinical evaluation


Platform | Type of candidate vaccine | Developer  |Coronavirus target | Current stage of clinical evaluation/regulatory status-Coronavirus candidate|Same platform for non-Coronavirus candidates |
|--------------------------|-------------------------------|----------------------------------|-------------------------|-----------------------|---------------------------------------|
|Non-Replicating Viral Vector| Adenovirus Type 5 Vector| CanSino Biological Inc./Beijing Institute of Biotechnology| COVID- 19 |Phase 2 ChiCTR Phase 1 ChiCTR| Ebola|


```
Non-
Replicating
Viral Vector
```
```
ChAdOx1 University of Oxford COVID- 19 Phase 1/
NCT
```
```
MERS, influenza,
TB, Chikungunya,
Zika, MenB, plague
DNA DNA plasmid
vaccine with
electroporation
```
```
Inovio Pharmaceuticals COVID- 19 Phase 1
NCT
```
```
multiple candidates
```
```
Inactivated Inactivated Wuhan Institute of
Biological
Products/Sinopharm
```
```
COVID- 19 Phase 1
ChiCTR
```
```
Inactivated Inactivated Beijing Institute of
Biological
Products/Sinopharm
```
```
COVID- 19 Phase 1
(regulatory approval)
```
```
Inactivated Inactivated +
alum
```
```
Sinovac COVID- 19 Phase 1
NCT
```
## SARS

```
RNA mRNA BioNTech/Fosun
Pharma/Pfizer
```
```
COVID- 19 Phase 1/
2020 - 001038 - 36
RNA LNP-
encapsulated
mRNA
```
```
Moderna/NIAID COVID- 19 Phase 1
NCT
```
```
multiple candidates
```
```
Platform Type of candidate
vaccine
```
```
Developer Coronavirus
target
```
```
Current stage of clinical
evaluation/regulatory
status- Coronavirus
candidate
```
```
Same platform
for non-
Coronavirus
candidates
DNA DNA with
electroporation
```
```
Karolinska Institute / Cobra
Biologics
(OPENCORONA Project)
```
```
COVID- 19 Pre-Clinical
```
```
DNA DNA plasmid vaccine Osaka University/ AnGes/ Takara
Bio
```
```
COVID- 19 Pre-Clinical
```
```
DNA DNA Takis/Applied DNA Sciences/Evvivax COVID- 19 Pre-Clinical
DNA Plasmid DNA,
Needle-Free
Delivery
```
```
Immunomic Therapeutics,
Inc./EpiVax, Inc./PharmaJet
```
```
COVID- 19 Pre-Clinical SARS
```
```
DNA DNA plasmid vaccine
Zydus Cadila COVID- 19 Pre-Clinical
```
```
DNA DNA vaccine BioNet Asia COVID- 19 Pre-Clinical
DNA DNA vaccine University of Waterloo COVID- 19 Pre-Clinical
DNA DNA vaccine Entos Pharmaceuticals COVID- 19 Pre-Clinical
Inactivated Inactivated Institute of Medical Biology ,
Chinese Academy of Medical
Sciences
```
```
COVID- 19 Pre-Clinical
```
```
Inactivated TBD Osaka University/ BIKEN/ NIBIOHN COVID- 19 Pre-Clinical
Inactivated Inactivated + CpG
1018
```
```
Sinovac/Dynavax COVID- 19 Pre-Clinical
```
```
Inactivated Inactivated + CpG
1018
```
```
Valneva/Dynavax COVID- 19 Pre-Clinical
```

**DISCLAIMER:**

**These landscape documents have been prepared by the World Health Organization (WHO) for information purposes only concerning the 2019-2020 global of the novel
coronavirus. Inclusion of any particular product or entity in any of these landscape documents does not constitute, and shall not be deemed or construed as, any
approval or endorsement by WHO of such product or entity (or any of its businesses or activities). While WHO takes reasonable steps to verify the accuracy of the
information presented in these landscape documents, WHO does not make any (and hereby disclaims all) representations and warranties regarding the accuracy,
completeness, fitness for a particular purpose (including any of the aforementioned purposes), quality, safety, efficacy, merchantability and/or non-infringement of any
information provided in these landscape documents and/or of any of the products referenced therein. WHO also disclaims any and all liability or responsibility
whatsoever for any death, disability, injury, suffering, loss, damage or other prejudice of any kind that may arise from or in connection with the procurement,**

```
Live
Attenuated
Virus
```
```
Codon deoptimized
live attenuated
vaccines
```
```
Codagenix/Serum Institute of India COVID- 19 Pre-Clinical HAV, InfA, ZIKV,
FMD, SIV, RSV,
DENV
Live
Attenuated
Virus
```
```
Codon deoptimized
live attenuated
vaccines
```
```
Indian Immunologicals Ltd/Griffith
University
```
```
COVID- 19 Pre-Clinical
```
```
Non-
Replicating
Viral Vector
```
```
MVA encoded VLP GeoVax/BravoVax COVID- 19 Pre-Clinical LASV, EBOV,
MARV, HIV
```
```
Non-
Replicating
Viral Vector
```
```
Ad26 Janssen Pharmaceutical Companies COVID- 19 Pre-Clinical Ebola, HIV, RSV
```
```
Non-
Replicating
Viral Vector
```
```
Replication
defective Simian
Adenovirus (GRAd)
encoding SARS-CoV-
2 S
```
```
ReiThera/LEUKOCARE/Univercells COVID- 19 Pre-Clinical
```
```
Non-
replicating
viral vector
```
```
MVA-S encoded DZIF – German Center for Infection
Research
```
```
COVID- 19 Pre-clinical Many
```
```
Non-
Replicating
Viral Vector
```
```
adenovirus-based
NasoVAX expressing
SARS2-CoV spike
protein
```
```
Altimmune COVID- 19 Pre-Clinical influenza
```
```
Non-
Replicating
Viral Vector
```
```
Ad5 S (GREVAX™
platform)
```
```
Greffex COVID- 19 Pre-Clinical MERS
```
```
Non-
Replicating
Viral Vector
```
```
Oral Ad5 S Stabilitech Biopharma Ltd COVID- 19 Pre-Clinical Zika, VZV, HSV-
2 and Norovirus
```
```
Non-
Replicating
Viral Vector
```
```
adenovirus-based +
HLA-matched
peptides
```
```
Valo Therapeutics Ltd Pan-Corona Pre-Clinical
```
```
Non-
Replicating
Viral Vector
```
```
Oral Vaccine
platform
```
```
Vaxart COVID- 19 Pre-Clinical InfA, CHIKV,
LASV, NORV;
EBOV, RVF,
HBV, VEE
Non-
Replicating
Viral Vector
```
```
MVA expressing
structural proteins
```
```
Centro Nacional Biotecnología
(CNB-CSIC), Spain
```
```
COVID- 19 Pre-Clinical Multiple
candidates
```
```
Non-
Replicating
Viral Vector
```
```
Dendritic cell-based
vaccine
```
```
University of Manitoba COVID- 19 Pre-Clinical
```
```
Non-
Replicating
Viral Vector
```
```
parainfluenza virus 5
(PIV5)-based vaccine
expressing the spike
protein
```
```
University of Georgia/University of
Iowa
```
```
COVID- 19 Pre-Clinical MERS
```
```
Non-
Replicating
Viral Vector
```
```
Recombinant
deactivated rabies
virus containing S
```
```
Bharat Biotech/Thomas Jefferson
University
```
```
COVID- 19 Pre-Clinical
```
```
Protein
Subunit
```
```
Capsid-like Particle AdaptVac (PREVENT-nCoV
consortium)
```
```
COVID- 19 Pre-Clinical
```
```
Protein
Subunit
```
```
Drosophila S2 insect
cell expression
system VLPs
```
```
ExpreS2ion COVID- 19 Pre-Clinical
```
```
Protein
Subunit
```
```
Peptide antigens
formulated in LNP
```
```
IMV Inc COVID- 19 Pre-Clinical
```
```
Protein
Subunit
```
```
S protein WRAIR/USAMRIID COVID- 19 Pre-Clinical
```
```
Protein
Subunit
```
```
S protein +Adjuvant National Institute of Infectious
Disease, Japan
```
```
COVID- 19 Pre-Clinical Influenza
```
```
Protein
Subunit
```
```
VLP-recombinant
protein + Adjuvant
```
```
Osaka University/ BIKEN/ National
Institutes of Biomedical Innovation,
Japan
```
```
COVID- 19 Pre-Clinical
```
```
Protein
Subunit
```
```
Native like Trimeric
subunit Spike
Protein vaccine
```
```
Clover Biopharmaceuticals
Inc./GSK/Dynavax
```
```
COVID- 19 Pre-Clinical HIV, REV
Influenza
```

**DISCLAIMER:**

**These landscape documents have been prepared by the World Health Organization (WHO) for information purposes only concerning the 2019-2020 global of the novel
coronavirus. Inclusion of any particular product or entity in any of these landscape documents does not constitute, and shall not be deemed or construed as, any
approval or endorsement by WHO of such product or entity (or any of its businesses or activities). While WHO takes reasonable steps to verify the accuracy of the
information presented in these landscape documents, WHO does not make any (and hereby disclaims all) representations and warranties regarding the accuracy,
completeness, fitness for a particular purpose (including any of the aforementioned purposes), quality, safety, efficacy, merchantability and/or non-infringement of any
information provided in these landscape documents and/or of any of the products referenced therein. WHO also disclaims any and all liability or responsibility
whatsoever for any death, disability, injury, suffering, loss, damage or other prejudice of any kind that may arise from or in connection with the procurement,**

```
Protein
Subunit
```
```
microneedle arrays
S1 subunit
```
```
Univ. of Pittsburgh COVID- 19 Pre-Clinical MERS
```
```
Protein
Subunit
```
```
Peptide Vaxil Bio COVID- 19 Pre-Clinical
```
```
Protein
Subunit
```
```
Adjuvanted protein
subunit (RBD)
```
```
Biological E Ltd COVID- 19 Pre-Clinical
```
```
Protein
Subunit
```
```
Peptide Flow Pharma Inc COVID- 19 Pre-Clinical Ebola,
Marburg, HIV,
Zika, Influenza,
HPV
therapeutic
vaccine,
BreastCA
vaccine
Protein
Subunit
```
```
S protein AJ Vaccines COVID- 19 Pre-Clinical
```
```
Protein
Subunit
```
```
Ii-Key peptide Generex/EpiVax COVID- 19 Pre-Clinical Influenza, HIV,
SARS-CoV
Protein
Subunit
```
```
S protein EpiVax/Univ. of Georgia COVID- 19 Pre-Clinical H7N
```
```
Protein
Subunit
```
```
S protein
(baculovirus
production)
```
```
Sanofi Pasteur/GSK COVID- 19 Pre-Clinical Influenza,
SARS-CoV
```
```
Protein
Subunit
```
```
Full length
recombinant SARs
CoV-2 glycoprotein
nanoparticle vaccine
adjuvanted with
Matrix M
```
```
Novavax COVID- 19 Pre-Clinical RSV; CCHF,
HPV, VZV,
EBOV
```
```
Protein
Subunit
```
```
gp-96 backbone Heat Biologics/Univ. Of Miami COVID- 19 Pre-Clinical NSCLC, HIV,
malaria, Zika
Protein
Subunit
```
```
Molecular clamp
stabilized Spike
protein
```
```
University of
Queensland/GSK/Dynavax
```
```
COVID- 19 Pre-Clinical Nipah,
influenza,
Ebola, Lassa
Protein
Subunit
```
```
Peptide vaccine FBRI SRC VB VECTOR,
Rospotrebnadzor, Koltsovo
```
```
COVID- 19 Pre-Clinical Ebola
```
```
Protein
Subunit
```
```
Subunit vaccine FBRI SRC VB VECTOR,
Rospotrebnadzor, Koltsovo
```
```
COVID- 19 Pre-Clinical
```
```
Protein
Subunit
```
```
S1 or RBD protein Baylor College of Medicine COVID- 19 Pre-Clinical SARS
```
```
Protein
Subunit
```
```
Subunit protein,
plant produced
```
```
iBio/CC-Pharming COVID- 19 Pre-Clinical
```
```
Protein
Subunit
```
```
Recombinant
protein,
nanoparticles (based
on S-protein and
other epitopes)
```
```
Saint-Petersburg scientific research
institute of vaccines and serums
```
```
COVID- 19 Pre-Clinical
```
```
Protein
Subunit
```
## COVID-19 XWG- 03

```
truncated S (spike)
proteins
```
```
Innovax/Xiamen Univ./GSK COVID- 19 Pre-Clinical HPV
```
```
Protein
Subunit
```
```
Adjuvanted
microsphere peptide
```
```
VIDO-InterVac, University of
Saskatchewan
```
```
COVID- 19 Pre-Clinical
```
```
Protein
Subunit
```
```
Synthetic Long
Peptide Vaccine
candidate for S and
M proteins
```
```
OncoGen COVID- 19 Pre-Clinical
```
```
Protein
Subunit
```
```
Oral E. coli-based
protein expression
system of S and N
proteins
```
```
MIGAL Galilee Research Institute COVID- 19 Pre-Clinical
```
```
Protein
Subunit
```
```
Nanoparticle vaccine LakePharma, Inc. COVID- 19 Pre-Clinical
```
```
Protein
Subunit
```
```
Recombinant spike
protein with Advax™
adjuvant
```
```
Vaxine Pty Ltd COVID- 19 Pre-Clinical
```
```
Protein
Subunit
```
```
Spike-based University of Alberta COVID- 19 Pre-Clinical Hepatitis C
```

**DISCLAIMER:**

**These landscape documents have been prepared by the World Health Organization (WHO) for information purposes only concerning the 2019-2020 global of the novel
coronavirus. Inclusion of any particular product or entity in any of these landscape documents does not constitute, and shall not be deemed or construed as, any
approval or endorsement by WHO of such product or entity (or any of its businesses or activities). While WHO takes reasonable steps to verify the accuracy of the
information presented in these landscape documents, WHO does not make any (and hereby disclaims all) representations and warranties regarding the accuracy,
completeness, fitness for a particular purpose (including any of the aforementioned purposes), quality, safety, efficacy, merchantability and/or non-infringement of any
information provided in these landscape documents and/or of any of the products referenced therein. WHO also disclaims any and all liability or responsibility
whatsoever for any death, disability, injury, suffering, loss, damage or other prejudice of any kind that may arise from or in connection with the procurement,**

```
Protein
Subunit
```
```
Recombinant S1-Fc
fusion protein
```
```
AnyGo Technology COVID- 19 Pre-Clinical
```
```
Protein
Subunit
```
```
Recombinant
protein
```
```
Yisheng Biopharma COVID- 19 Pre-Clinical
```
```
Protein
Subunit
```
```
Recombinant S
protein in IC-BEVS
```
```
Vabiotech COVID- 19 Pre-Clinical
```
```
Replicating
Viral Vector
```
```
YF17D Vector KU Leuven COVID- 19 Pre-Clinical
```
```
Replicating
Viral Vector
```
```
Measles Vector Zydus Cadila COVID- 19 Pre-Clinical
```
```
Replicating
Viral Vector
```
```
Measles Vector Institute Pasteur/Themis/Univ. of
Pittsburg Center for Vaccine
Research
```
```
COVID- 19 Pre-Clinical West nile, chik,
Ebola, Lassa,
Zika
Replicating
Viral Vector
```
```
Measles Vector FBRI SRC VB VECTOR,
Rospotrebnadzor, Koltsovo
```
```
COVID- 19 Pre-Clinical
```
```
Live
attenuated
virus
```
```
Measles Virus (S, N
targets)
```
```
DZIF – German Center for Infection
Research
```
```
COVID- 19 Pre-clinical Zika, H7N9,
CHIKV
```
```
Replicating
Viral Vector
```
```
Horsepox vector
expressing S protein
```
```
Tonix Pharma/Southern Research COVID- 19 Pre-Clinical Smallpox,
monkeypox
Replicating
Viral Vector
```
```
Live viral vectored
vaccine based on
attenuated influenza
virus backbone
(intranasal)
```
```
BiOCAD and IEM COVID- 19 Pre-Clinical Influenza
```
```
Replicating
Viral Vector
```
```
Recombinant
vaccine based on
Influenza A virus, for
the prevention of
COVID- 19
(intranasal)
```
## FBRI SRC VB VECTOR,

```
Rospotrebnadzor, Koltsovo
```
```
COVID- 19 Pre-Clinical Influenza
```
```
Replicating
Viral Vector
```
```
Influenza vector
expressing RBD
```
```
University of Hong Kong COVID- 19 Pre-Clinical
```
```
Replicating
Viral Vector
```
```
Replication-
competent VSV
chimeric virus
technology (VSVΔG)
delivering the SARS-
CoV-2 Spike (S)
glycoprotein.
```
```
IAVI/Batavia COVID- 19 Pre-Clinical Ebola,
Marburg, Lassa
```
```
Replicating
Viral Vector
```
```
VSV-S University of Western Ontario COVID- 19 Pre-Clinical HIV, MERS
```
```
Replicating
Viral Vector
```
```
VSV vector FBRI SRC VB VECTOR,
Rospotrebnadzor, Koltsovo
```
```
COVID- 19 Pre-Clinical
```
```
Replicating
Viral Vector
```
```
M2-deficient single
replication (M2SR)
influenza vector
```
```
UW–Madison/FluGen/Bharat
Biotech
```
```
COVID- 19 Pre-Clinical influenza
```
```
RNA LNP-encapsulated
mRNA cocktail
encoding VLP
```
```
Fudan University/ Shanghai
JiaoTong University/RNACure
Biopharma
```
```
COVID- 19 Pre-Clinical
```
```
RNA LNP-encapsulated
mRNA encoding RBD
```
```
Fudan University/ Shanghai
JiaoTong University/RNACure
Biopharma
```
```
COVID- 19 Pre-Clinical
```
```
RNA Replicating
Defective SARS-CoV-
2 derived RNAs
```
```
Centro Nacional Biotecnología
(CNB-CSIC), Spain
```
```
COVID- 19 Pre-Clinical
```
```
RNA LNP-encapsulated
mRNA
```
```
University of Tokyo/ Daiichi-Sankyo COVID- 19 Pre-Clinical MERS
```
```
RNA Liposome-
encapsulated mRNA
```
```
BIOCAD COVID- 19 Pre-Clinical
```
```
RNA Several mRNA
candidates
```
```
RNAimmune, Inc. COVID- 19 Pre-Clinical
```
```
RNA mRNA FBRI SRC VB VECTOR,
Rospotrebnadzor, Koltsovo
```
```
COVID- 19 Pre-Clinical
```
```
RNA mRNA China CDC/Tongji
University/Stermina
```
```
COVID- 19 Pre-Clinical
```

**DISCLAIMER:**

**These landscape documents have been prepared by the World Health Organization (WHO) for information purposes only concerning the 2019-2020 global of the novel
coronavirus. Inclusion of any particular product or entity in any of these landscape documents does not constitute, and shall not be deemed or construed as, any
approval or endorsement by WHO of such product or entity (or any of its businesses or activities). While WHO takes reasonable steps to verify the accuracy of the
information presented in these landscape documents, WHO does not make any (and hereby disclaims all) representations and warranties regarding the accuracy,
completeness, fitness for a particular purpose (including any of the aforementioned purposes), quality, safety, efficacy, merchantability and/or non-infringement of any
information provided in these landscape documents and/or of any of the products referenced therein. WHO also disclaims any and all liability or responsibility
whatsoever for any death, disability, injury, suffering, loss, damage or other prejudice of any kind that may arise from or in connection with the procurement,**

```
RNA mRNA Arcturus/Duke-NUS COVID- 19 Pre-Clinical multiple
candidates
```
```
RNA saRNA Imperial College London COVID- 19 Pre-Clinical EBOV; LASV,
MARV, Inf
(H7N9), RABV
RNA mRNA Curevac COVID- 19 Pre-Clinical RABV, LASV,
YFV; MERS,
InfA, ZIKV,
DengV, NIPV
RNA mRNA in an
intranasal delivery
system
```
```
eTheRNA COVID- 19 Pre-Clinical
```
```
VLP Virus-like particle,
based on RBD
displayed on virus-
like particles
```
```
Saiba GmbH COVID- 19 Pre-Clinical
```
```
VLP Plant-derived VLP Medicago Inc. COVID- 19 Pre-Clinical Flu, Rotavirus,
Norovirus,
West Nile virus,
Cancer
VLP ADDomerTM
multiepitope display
```
```
Imophoron Ltd and Bristol
University’s Max Planck Centre
```
```
COVID- 19 Pre-Clinical
```
```
VLP Unknown Doherty Institute COVID- 19 Pre-Clinical
```
```
VLP VLP OSIVAX COVID- 19
& SARS
```
```
Pre-Clinical
```
```
VLP eVLP ARTES Biotechnology COVID- 19 Pre-Clinical malaria
```
```
Unknown Unknown ImmunoPrecise COVID- 19 Pre-Clinical
```
```
Unknown Unknown Tulane University COVID- 19 Pre-Clinical
```
```
Unknown Unknown Université Laval COVID- 19 Pre-Clinical
```

